RismadarVoice Reporters
March 22, 2026
A surge in demand has greeted the introduction of Lenacapavir, a newly approved injectable drug for the prevention of Human Immunodeficiency Virus (HIV), as Nigerians scramble to access it ahead of its nationwide rollout.
Findings indicate that individuals across several states, particularly those familiar with pre-exposure prophylaxis (PrEP), have been approaching health facilities and non-governmental organizations in search of the injection, even as the Federal Government commences phased deployment in selected pilot locations.
Lenacapavir, developed by Gilead Sciences and endorsed by the World Health Organization in July 2025, is a long-acting HIV prevention option administered twice yearly.
It offers an alternative to daily oral PrEP pills, with experts saying it could significantly improve adherence among users.
Nigeria currently has an estimated two million people living with HIV, according to recent data from the National Agency for the Control of AIDS and UNAIDS, underscoring the importance of expanding prevention options.
The Federal Ministry of Health and Social Welfare, through the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), confirmed the receipt of an initial batch of the injection earlier this month.
A total of 52,000 doses are expected, with 11,520 already delivered.
Nine states: Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, Gombe, Kano, Kwara, and Lagos as well as the Federal Capital Territory, have been selected for the pilot phase, with an official unveiling scheduled for March 24.
Health officials say the injection will be administered free at designated public health facilities, including general hospitals, while healthcare workers are currently undergoing training on proper administration protocols.
Rising demand, mixed awareness
Reports from states such as Anambra, Benue, and Osun point to strong public interest in the injection, particularly among high-risk groups, including discordant couples where one partner is HIV-positive and the other is not.
A representative of the Network of People Living with HIV/AIDS in Nigeria (NEPWHAN) said demand has been high within affected communities, with many individuals making inquiries even before the drug’s arrival.
Similarly, health workers in some states have expressed interest in being among the first recipients, citing its preventive benefits.
In Anambra, an NGO worker confirmed that the drug had already been distributed to selected facilities, although she noted that misconceptions persist.
“Some people believe it is a cure for HIV, which is not correct. It is strictly for prevention,” she said.
Experts and advocacy groups have continued to emphasise that Lenacapavir is not a treatment for those already infected with HIV but a preventive measure for HIV-negative individuals at risk.
Access expands across states
State governments have begun designating facilities for rollout.
In Kwara State, the injection is already available in six centres, including Specialist Hospital Offa and Sobi Specialist Hospital, while Akwa Ibom has identified nine facilities in preparation for its arrival.
Officials confirmed that access to the injection will be free for eligible individuals under the government’s public health programme.
Experts urge caution, proper regulation
Despite the excitement, health professionals have called for careful implementation.
The Pharmaceutical Society of Nigeria (PSN) warned that the rollout must strictly follow regulatory guidelines to ensure safety and efficacy.
PSN President, Ayuba Tanko said relevant agencies, including the National Agency for Food and Drug Administration and Control (NAFDAC), must complete all necessary evaluations before wider distribution.
“As promising as this drug is, its deployment must be guided by science and strict safeguards,” he said.
Medical experts also noted that the injection is currently recommended only for non-pregnant individuals, with ongoing training for healthcare providers to ensure proper usage.
Hope for reducing new infections
Stakeholders say early adoption of Lenacapavir could play a critical role in reducing new HIV infections, particularly among vulnerable populations, while helping to address longstanding challenges with adherence to daily preventive medication.
However, they stress that increased awareness, accurate information, and sustained government commitment will be key to maximising its impact in Nigeria’s fight against HIV.
